Canbisol

Canbisol
Clinical data
Drug class	Cannabinoid
ATC code	none;
Identifiers
	IUPAC name (6aR,9R,10aR)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,8,9,10,10a-hexahydrobenzo[c]chromene-1,9-diol;
CAS Number	56689-43-1 ;
PubChem CID	41969;
ChemSpider	16736847 ;
UNII	NZ1ZPC4WSF;
ChEMBL	ChEMBL2105525 ;
CompTox Dashboard (EPA)	DTXSID00866582 ;
Chemical and physical data
Formula	C24H38O3
Molar mass	374.565 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Oc1cc(C(C)(C)CCCCCC)cc(c1C2C3)OC(C)(C)C2CCC3O;
	InChI InChI=1S/C24H38O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,17-19,25-26H,6-12,15H2,1-5H3/t17?,18-,19-/m0/s1 ; Key:UEKGZFCGRQYMRM-MNNMKWMVSA-N ;
	(what is this?) (verify)

Canbisol (Nabidrox) is a synthetic cannabinoid derivative that is the dimethylheptyl homologue of 9-nor-9β-hydroxyhexahydrocannabinol (HHC). It is a potent agonist at both the CB₁ and CB₂ receptors, with a binding affinity of 0.1 nM at CB₁ and 0.2 nM at CB₂. It is mainly used in scientific research, in receptor binding studies to determine the structure and function of the cannabinoid receptors, but has been made illegal in some countries due to its possible abuse potential as a cannabinomimetic drug.